Inivata's John Beeler On The Future Of Liquid Biopsies
John Beeler, vice-president of corporate and business development at Inivata, speaks to Scrip's Lucie Ellis about how the company's technology is aligned with the current genomic medicine revolution facing the pharmaceutical industry.
You may also be interested in...
Health care funding in the first half of 2020 reached $10.4bn, according to a mid-year report from Silicon Valley Bank, nearly matching 2019’s full-year record. As well as the COVID-19 pandemic though, other global events, such as the US election, could become distractions in the second half of the year.
In this latest installment of VC Playbook, Chris Buyse – former chief financial officer of ThromboGenics – talks to In Vivo about the lessons he has learned from a career as a financial executive in the life sciences and his current venture, Fund+, a Belgian-based investment group focused on innovative companies primarily active in therapeutics R&D.
A selection of articles you might have missed from July 2020, including exclusive interviews with industry leaders and a review of Q2 financing statistics.